



Express Mail No.: EV473971064US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava et al. Confirmation No.: 1804  
Serial No.: 09/668,724 Art Unit: 1642  
Filed: September 22, 2000 Examiner: Reddig, Peter J.  
For: ALPHA (2) MACROGLOBULIN Attorney Docket No: 8449-128-999  
RECEPTOR AS A HEAT SHOCK  
PROTEIN RECEPTOR AND USES  
THEREOF

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56 AND 1.97**

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants respectfully direct the Examiner's attention to references **A14 and A15** and **C115 to C122** listed on the attached List of References Cited by Applicants.

Copies of references **A14 and C115 to C122** are submitted herewith. A copy of reference **A15** is not submitted herewith because it is a U.S. patent. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application. Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicant that such references are available as "prior art" against the subject application.

NYI-3957524v1 1 03/26/2007 AAD0F01 00000017 503013 09668724  
01 FC:1806 180.00 DA

Pursuant to 37 C.F.R. §1.97(b), since it is believed that this information disclosure statement is being filed after the mailing date of a first Office Action on the merits, a fee of \$180.00 is believed to be due in connection herewith. Please charge the required fee to Jones Day deposit account no. 50-3013.

Respectfully submitted,

Date March 21, 2007

 32,605  
Adriane M. Antler (Reg. No.)

JONES DAY  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939

Enclosure



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-128-999	09/668,724
	APPLICANT Srivastava et al.	
	FILING DATE September 22, 2000	ART UNIT 1642

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A14	09/393,652	9/10/99	Srivastava	
	A15	7,179,462 B2	2/20/07	Srivastava	

### FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C115	Abbas, Lichtman, and Pober, 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	
	C116	Janeway, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V, Sections 13-1 to 13-15)	
	C117	Chandawarkar et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
	C118	Steinman, L., 2001, "Myelin-specific CD8+ T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30	
	C119	SenGupta et al., 2004, "Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA Class I and Class II," J. Immunol. 173:1987-1993	
	C120	Srivastava et al., 1986, "Tumor rejection antigens of chemically induced sarcomas of inbred mice," Proc. Natl. Acad. Sci. U.S.A. 83:3407-3411	
	C121	Rapley, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54	
	C122	Costanzo, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.